Malta - angleščina - Medicines Authority

morningside healthcare (malta) ltd 93, mill street, qormi, qrm 3102 , malta - methotrexate - tablet - methotrexate 2.5 mg - immunosuppressants

Singapur - angleščina - HSA (Health Sciences Authority)

orion pharma (sg) pte. ltd. - methotrexate disodium eqv methotrexate - tablet - methotrexate disodium eqv methotrexate 2.5mg

Irska - angleščina - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals ltd - methotrexate - tablet - 2.5 milligram(s) - other immunosuppressants; methotrexate

Irska - angleščina - HPRA (Health Products Regulatory Authority)

morningside healthcare ltd - methotrexate - tablet - 2.5 milligram(s) - other immunosuppressants; methotrexate

Irska - angleščina - HPRA (Health Products Regulatory Authority)

morningside healthcare ltd - methotrexate - tablet - 10 milligram(s) - other immunosuppressants; methotrexate

Evropska unija - angleščina - EMA (European Medicines Agency)

eli lilly netherlands - pemetrexed - carcinoma, non-small-cell lung; mesothelioma - antineoplastic agents - malignant pleural mesotheliomapemetrexed lilly in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.non-small cell lung cancerpemetrexed lilly in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.pemetrexed lilly is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.pemetrexed lilly is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non small cell lung cancer other than predominantly squamous cell histology.

Evropska unija - angleščina - EMA (European Medicines Agency)

sandoz gmbh - pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastic agents - malignant pleural mesothelioma pemetrexed sandoz in combination with cisplatin is indicated for the treatment of chemotherapy naive patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer pemetrexed sandoz in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sandoz is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed sandoz is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - methotrexate - oral tablet - 2.5mg

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - methotrexate - oral tablet - 10mg

Irska - angleščina - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - methotrexate - concentrate for solution for infusion - 100 milligram(s)/millilitre - folic acid analogues; methotrexate